Legend Biotech Corporation (NASDAQ:LEGN) Q1 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Legend Biotech’s First Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode.
Legend Biotech Corporation (LEGN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Hillhouse Capital Management Lei Zhang | 5,984,550 | $203,055,782 | 5.74% | |
| 2. | Suvretta Capital Management Aaron Cowen | 3,749,965 | $127,236,312 | +8% | 4.72% |
| 3. | Braidwell LP Alex Karnal | 2,977,951 | $101,041,877 | 3.55% | |
| 4. | Deerfield Management James E. Flynn | 1,743,555 | $59,158,821 | +13% | 1.17% |
| 5. | Millennium Management Israel Englander | 858,489 | $29,128,532 | +237% | 0.02% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,204,213 | $448,018,916 | 0.03% | |
| 2. | 6,917,567 | $234,713,042 | 1.14% | |
| 3. | 4,527,000 | $153,601,109 | 0% | |
| 4. | 2,936,703 | $99,642,333 | 0.02% | |
| 5. | 2,270,264 | $77,030,058 | 0.03% |
News See All
20 Takeover Rumors Hedge Funds Are Buying
Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market.
Legend Biotech Corporation (NASDAQ:LEGN) Q4 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Legend Biotech Fourth Quarter and Full-Year 2024 Earnings Call. At this time, all participants are in a listen-only mode.
10 Oversold Pharma Stocks to Buy According to Analysts
On February 20, Emily Field, Head of European Pharma Research at Barclays, appeared on CNBC to discuss the dynamics of the pharmaceutical sector, the impact of US tariffs, and the performance of obesity...
Market Concerns Put Pressure on Legend Biotech Corporation (LEGN) Shares
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Contrarian Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Best Mid-Cap Growth Stocks to Buy According to Analysts
Investing in mid-cap growth stocks has long been a favoured strategy for investors looking to strike a balance between the stability of large-cap companies and the high-growth potential of smaller firms...
12 Best Healthcare Stocks to Buy According to Analysts
McKinsey reported that, since 2019, the US healthcare industry witnessed significant financial pressure.
12 Stocks That Will Double in 2025
A lot is happening in the market, especially within the growth sectors.
12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
10 Best Up and Coming Stocks To Buy According to Analysts
Donald Trump's victory in the recent presidential election is expected to encourage companies that have been hesitant to pursue IPOs in 2025, capitalizing on the positive market reaction and anticipated...